PMID- 32370739
OWN - NLM
STAT- MEDLINE
DCOM- 20201216
LR  - 20201216
IS  - 1471-2407 (Electronic)
IS  - 1471-2407 (Linking)
VI  - 20
IP  - 1
DP  - 2020 May 5
TI  - Cisplatin-based chemotherapy with or without bevacizumab for Chinese 
      postmenopausal women with advanced cervical cancer: a retrospective observational 
      study.
PG  - 381
LID - 10.1186/s12885-020-06854-w [doi]
LID - 381
AB  - BACKGROUND: The purpose of this study was to assess the efficacy and safety of 
      cisplatin-based chemotherapy with or without bevacizumab (BEV) in Chinese women 
      with advanced cervical cancer (ACC). METHODS: For this observational study, we 
      analysed the data of 316 Chinese women with ACC who were treated at the Henan 
      provincial people's hospital between Jan 1, 2014, and Dec 31, 2018, with 
      cisplatin-based chemotherapy plus BEV (CB) or cisplatin-based chemotherapy alone 
      (CA) until disease progression, unacceptable toxicity, or death. The co-primary 
      endpoints were overall survival (OS) and progression-free survival (PFS); the 
      secondary endpoint was the occurrence of adverse events (AEs). RESULTS: A total 
      of 264 patients with ACC were included in the assessment (CB, n = 130 and CA, 
      n = 134). At a median follow-up of 38 months (IQR 36-40), the median OS in the CB 
      cohort was significantly longer than that in the CA cohort (hazard ratio [HR] 
      1.21, 95% confidence interval[CI] 1.14-1.73; p = 0.002); additionally, the median 
      PFS was 345 days (95% CI, 318-372) for CB and 261 days (95% CI, 165-357) for 
      CA(HR 1.61, 95% CI 1.12-2.17; p = 0.000). Significant differences were noted 
      between groups in terms of thrombosis/embolism, neutropenia, and febrile 
      neutropenia. CONCLUSIONS: In Chinese women with ACC, cisplatin-based chemotherapy 
      plus BEV is associated with improved survival compared to cisplatin-based 
      chemotherapy alone. This finding suggests a positive survival benefit of 
      anti-angiogenesis therapy in this population.
FAU - He, Xiaoli
AU  - He X
AD  - Department of Gynaecology, Henan Provincial People's Hospital, People's Hospital 
      of Zhengzhou University, People's Hospital of Henan University, No. 7, Weiwu 
      Road, Jinshui District, Zhengzhou, 450000, China.
FAU - Liu, Jun
AU  - Liu J
AD  - Department of Gynaecology, The First Affiliated Hospital, Sun Yat-sen University, 
      No. 58, Zhongshan 2nd Road, Yuexiu District, Guangzhou, 510080, China.
FAU - Xiao, Li
AU  - Xiao L
AD  - Department of Gynaecology and Obstetrics, The Central Hospital of Wuhan, Tongji 
      Medical College, Huazhong University of Science and Technology, No. 26, Shengli 
      Street, Jiang'an District, Wuhan, 430014, Hubei, China.
FAU - Zhao, Mingdong
AU  - Zhao M
AD  - Department of Orthopaedics, Jinshan Hospital, Fudan University, Longhang Road No. 
      1508, Jinshan District, Shanghai, 201508, China.
FAU - Su, Tingting
AU  - Su T
AD  - Department of Gynaecology, The Obstetrics and Gynecology Hospital of Fudan 
      University, No. 419, Fangxie Road, Huangpu District, Shanghai, 200011, China.
FAU - Liu, Tiejian
AU  - Liu T
AD  - Department of Neurosurgery, The Third Affiliated Hospital of Southern Medical 
      University, No.183, Zhongshan avenue west, Tianhe District, Guangzhou, 510630, 
      China.
FAU - Han, Guowei
AU  - Han G
AD  - Department of Orthopaedics, The First Affiliated Hospital, Sun Yat-sen 
      University, No. 58, Zhongshan 2nd Road, Yuexiu District, Guangzhou, 510080, 
      China.
FAU - Wang, Yue
AU  - Wang Y
AD  - Department of Gynaecology, Henan Provincial People's Hospital, People's Hospital 
      of Zhengzhou University, People's Hospital of Henan University, No. 7, Weiwu 
      Road, Jinshui District, Zhengzhou, 450000, China. xjk0328@163.com.
LA  - eng
GR  - 2014-403/Shanghai Municipal Population and Family Planning Commission/
GR  - 201640057/Shanghai Municipal Population and Family Planning Commission/
PT  - Journal Article
PT  - Observational Study
DEP - 20200505
PL  - England
TA  - BMC Cancer
JT  - BMC cancer
JID - 100967800
RN  - 2S9ZZM9Q9V (Bevacizumab)
RN  - Q20Q21Q62J (Cisplatin)
SB  - IM
MH  - Aged
MH  - Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
MH  - Bevacizumab/administration & dosage
MH  - Cisplatin/administration & dosage
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Neoplasm Staging
MH  - *Postmenopause
MH  - Prognosis
MH  - Retrospective Studies
MH  - Survival Rate
MH  - Uterine Cervical Neoplasms/*drug therapy/pathology
PMC - PMC7201988
OTO - NOTNLM
OT  - Bevacizumab
OT  - Cervical cancer
OT  - Chemotherapy
OT  - Overall survival
OT  - Progression-free survival
COIS- The authors declare that they have no competing interests.
EDAT- 2020/05/07 06:00
MHDA- 2020/12/17 06:00
PMCR- 2020/05/05
CRDT- 2020/05/07 06:00
PHST- 2019/05/31 00:00 [received]
PHST- 2020/04/12 00:00 [accepted]
PHST- 2020/05/07 06:00 [entrez]
PHST- 2020/05/07 06:00 [pubmed]
PHST- 2020/12/17 06:00 [medline]
PHST- 2020/05/05 00:00 [pmc-release]
AID - 10.1186/s12885-020-06854-w [pii]
AID - 6854 [pii]
AID - 10.1186/s12885-020-06854-w [doi]
PST - epublish
SO  - BMC Cancer. 2020 May 5;20(1):381. doi: 10.1186/s12885-020-06854-w.